Deryl Troyer
There is emerging and convincing data that certain cells, administered systemically, have a natural propensity to migrate to cancerous tissues in preclinical models. Examples of such cells include neural stem cells, bone marrow mesenchymal stem cells, umbilical cord Wharton’s jelly stem cells [3], and defensive cells.This homing ability can be exploited by using cells as stealth vehicles to ferry therapeutic nanomaterials to tumors to facilitate penetration, reduce potential toxicity, reduce potential unwanted immune consequences, and reduce removal by the reticuloendothelial system (RES).
PDFShare this article
Cancer Science & Therapy received 5332 citations as per Google Scholar report